Gene-Delivery Method Generates Immune Checkpoint Antibodies In Vivo

Share this content:
A new drug-delivery method could allow for less-frequent administration and formulations that are easier to manufacture.
A new drug-delivery method could allow for less-frequent administration and formulations that are easier to manufacture.

In a proof-of-principle study in mice, researchers showed that DNA-encoded plasmids can be used to generate antibodies to immune checkpoint molecules, known as DNA-encoded monoclonal antibodies (DMAbs), to shrink tumors. The DMAb platform, used to deliver anti-CTLA-4 monoclonal antibodies (mAbs), can be retooled to encode for other monoclonal antibodies in vivo, such as those targeting PD-1, and may offer advantages over traditional mAbs, such as reduced manufacturing complexity and lower costs. The study was recently published in Cancer Research.1

“It's really a demonstration of a new and upcoming technology,” senior author David Weiner, PhD, executive vice president and director of the Vaccine & Immunotherapy Center at The Wistar Institute, Philadelphia, Pennsylvania, told Cancer Therapy Advisor. “A very short time ago, most people did not think this kind of technology could produce a protein of value inside a living animal like this.”

Continue Reading Below

DNA-encoded plasmids have historically been perceived as lacking the ability to generate sufficient protein expression within an organism and therefore, were never widely pursued as a technology for gene therapies. “It was a second-class citizen to viral vectors. It just never could produce enough to generate a protein level that might be of use,” Dr Weiner said. “If you can demonstrate a protein level that might be of use, now there's a lot of possibility.”

To demonstrate the utility of the DMAb platform, researchers from The Wistar Institute and Inovio Pharmaceuticals engineered DNA-encoded plasmids to generate antibodies against immune checkpoint inhibitor CTLA-4. The DMAbs were injected into the muscle of mice and in vivo electroporation was used to facilitate delivery of the plasmid to the target muscle cells.

In mouse models, a single intramuscular injection of DMAbs resulted in high serum levels of antibodies to CTLA-4 and also, tumor regression. DMAbs were engineered to express checkpoint inhibitors ipilimumab (ipi-DMab) and tremelimumab (treme-DMab), and both antibodies were expressed at high levels in mouse models. Ipilimumab reached a peak level of approximately 85 mg/mL and tremelimumab reached a peak level of approximately 58 mg/mL. Both antibodies had prolonged expression that lasted for more than 1 year at 15 mg/mL. In addition, an in vitro functional T-cell activation assay showed that the DMAbs for ipilimumab and tremelimumab each produced functional antibodies that could induce T-cell activation.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs